甲磺酸普立地诺注射液的临床前研究
发布时间:2019-06-11 20:46
【摘要】:甲磺酸普立地诺(pridinol mesylate)是一种中枢性抗胆碱药,通过拮抗M型受体(主要为M1和M4受体亚型),具有抗乙酰胆碱的作用,能够改善帕金森患者的运动障碍症状,延迟患者的致残时间,减轻患者的痛苦。其次普立地诺对肌肉痉挛有明显的松弛效应,主要作用于大脑皮层和脑干网状结构,对脊柱运动神经元的反射活动产生抑制作用,是一种中枢性骨骼肌松弛药,临床应用于肌肉痉挛及伴有疼痛或收缩的运动障碍性疾病。 甲磺酸普立地诺收载于《日本药局方外》2002年版,《中国药典》尚未见其收载,中国对其相关报道较少亦无相关产品上市,仅见本课题组申请的发明专利。依据中国《药品注册管理办法》中“化学药品注册分类”要求,本文对所研制的甲磺酸普立地诺注射液进行了临床前的部分研究,旨在为该注射液的注册积累资料。 1.处方工艺研究。通过对甲磺酸普立地诺基本理化性质的考察,筛选注射液的最佳pH值范围和pH缓冲剂种类及其用量,确定甲磺酸普立地诺注射液最优处方:0.2%甲磺酸普立地诺、1.0%牛磺酸、0.1%焦亚硫酸钠、0.7%氯化钠、0.4%氢氧化钠溶液适量调节pH值至6.5-7.5。在处方中牛磺酸为pH缓冲剂,焦亚硫酸钠为抗氧剂,氯化钠为等渗调节剂,氢氧化钠为pH调节剂。用此处方并按常规制备工艺所制备的甲磺酸普立地诺注射液澄明、稳定,渗透压合格,pH适宜,含量准确。甲磺酸普立地诺注射液的规格为1mL:2mg。 2.质量标准研究。对甲磺酸普立地诺注射液进行了鉴别、检查和含量测定等研究。结果,鉴别项目均为阳性;检查项目符合《中国药典》注射液项下相关要求;采用反相HPLC法测定甲磺酸普立地诺注射液的含量,其色谱有条件为:色谱柱为Ultimate XB C18柱,以甲醇:0.1%磷酸(7:3,v/v)其中含4mmol/L辛烷磺酸钠为流动相,检测波长215nm,流速为1.OmL/min,柱温为30℃,进样量为20μL。 3.稳定性研究。影响因素试验,包括高温试验(60℃温度下放置10天),强光照试验(4500±500Lx放置10天);加速试验(温度为40℃±2℃、相对湿度为75%±5%的条件下放置6个月,仪器的温度控制在±2℃,湿度控制在±5%);长期试验(温度为25℃±2℃、相对湿度为60%±5%的条件下放置12个月,仪器的温度控制在±2℃,湿度控制在±5%)。结果:在影响因素和加速试验中,甲磺酸普立地诺注射液的性状、澄明度、含量、pH值等指标未见明显变化;目前长期试验考察至12个月,各项指标无明显变化,但长期试验有待继续考察至36个月。 4.一般药理学研究。考察了高、中、低3个不同剂量的甲磺酸普立地诺注射液对实验动物中枢神经系统、心血管系统和呼吸系统的影响。结果,该药对KM小鼠的一般行为和协调功能与对照组相比无明显改变;对阈下剂量戊巴比妥钠的催眠作用亦无协同作用;该药对SD大鼠的血压、心电图、心率和呼吸频率亦无明显影响。 5.安全性评价。采用改良寇氏法测定甲磺酸普立地诺注射液的LD50,常规法测定该药对新西兰兔的溶血性、肌肉和血管刺激性。结果,甲磺酸普立地诺注射液LD50=82.05mg/kg,95%可信范围为72.49mg/kg-92.83mg/kg,其LD50是正常人口服给药剂量的1025.5倍,说明甲磺酸普立地诺注射液安全性高。甲磺酸普立地诺注射液对新西兰兔无明显的溶血性、肌肉和血管刺激性,说明该药可用于肌肉注射给药,也适用于静脉注射给药。 6.药代动力学研究。采用新西兰兔动物实验,建立了甲磺酸普立地诺血药浓度测定方法。运用DAS2.0实用药代动力学程序软件分析血药浓度,甲磺酸普立地诺在新西兰兔体内过程符合有吸收的二室开放模型。单次肌肉注射甲磺酸普立地诺后,达峰浓度、达峰时间、药时曲线下面积和清除率等药代参数提示甲磺酸普立地诺具有线性动力学特征,其甲磺酸普立地诺的平均吸收半衰期T1/2为0.263h,达峰时间Tmax为0.517h,说明甲磺酸普立地诺注射液在新西兰兔肌注部位吸收迅速。肌注后药物在24小时的表观分布容积AUC为4.858μ g/mL*h,表明该注射液进入体内广泛分布。
[Abstract]:Pridin mesylate, a central anticholinergic agent, is a central anticholinergic drug, which has the effects of anti-ethmocholine by antagonizing M-type receptors (mainly of M1 and M4 receptor subtypes), and can improve the symptoms of dyskinesia in the patients of Parkinson's disease, delay the disabling time of the patients, and alleviate the suffering of the patients. secondly, the psite has obvious relaxation effect on the muscle spasm, mainly acts on the cerebral cortex and the brain stem net structure, and has the inhibition effect on the reflex activity of the spinal motoneurons, and is a central skeletal muscle relaxant, The clinical application is applied to the muscle spasm and the movement disorder with pain or contraction. The site of p. mesilate is listed in the 2002 edition of the
本文编号:2497444
[Abstract]:Pridin mesylate, a central anticholinergic agent, is a central anticholinergic drug, which has the effects of anti-ethmocholine by antagonizing M-type receptors (mainly of M1 and M4 receptor subtypes), and can improve the symptoms of dyskinesia in the patients of Parkinson's disease, delay the disabling time of the patients, and alleviate the suffering of the patients. secondly, the psite has obvious relaxation effect on the muscle spasm, mainly acts on the cerebral cortex and the brain stem net structure, and has the inhibition effect on the reflex activity of the spinal motoneurons, and is a central skeletal muscle relaxant, The clinical application is applied to the muscle spasm and the movement disorder with pain or contraction. The site of p. mesilate is listed in the 2002 edition of the
本文编号:2497444
本文链接:https://www.wllwen.com/yixuelunwen/yiyaoxuelunwen/2497444.html
最近更新
教材专著